Small Intestinal Bacterial Overgrowth (SIBO) - Prevention and Therapeutic Role of Nutrition, Prebiotics, Probiotics, and Prokinetics

Small Intestinal Bacterial Overgrowth (SIBO) is a condition marked by an increased proliferation of bacteria in the small intestine. This leads to a range of GI symptoms and nutritional issues. This article examines the preventive and therapeutic roles of nutrition, prebiotics, probiotics, and prokinetics in managing SIBO. Finding the prevalence of SIBO in the general population is challenging due to challenges in diagnosis and different diagnostic methods. Nevertheless, SIBO has been linked to several clinical conditions, such as obesity, celiac disease, irritable bowel syndrome, inflammatory bowel disease, and hepatic cirrhosis. The connection between SIBO and obesity remains controversial and unclear, with contraindicating evidence regarding its prevalence and association with body mass index (BMI). Anatomical changes from surgeries may also contribute to the development of SIBO, and disruptions in the migrating motor complex (MMC) can facilitate intestinal permeability. SIBO can lead to significant malabsorption of nutrients, including carbohydrates, fats, proteins, and iron, resulting in deficiencies and malnourishment. Additionally, increased levels of immunoglobulins observed point toward a possible immune response to bacterial overgrowth. Hence, understanding the prevalence, clinical manifestations, and nutritional impacts of SIBO is crucial for effective prevention and management. This article underscores the potential benefits of nutrition, including prebiotics and probiotics, in modulating gut microbiota and managing SIBO. Furthermore, prokinetics that enhance gastrointestinal motility may offer possible therapeutic advantages in the future. Continued research is necessary to clarify the underlying mechanisms and refine treatment strategies for SIBO.